Investigating how SOX2 modifications affect cancer cell growth and differentiation
Post-translational SOX2 modification - a regulatory switch between self-renewal and differentiation in squamous cell carcinoma
['FUNDING_R01'] · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · NIH-10988246
This study is looking at how a protein called SOX2 affects skin cancer, specifically squamous cell carcinoma, by seeing how changes to this protein influence cancer stem cells and their growth, which could help develop new treatments for patients with this type of cancer.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | NEW YORK UNIVERSITY SCHOOL OF MEDICINE (nih funded) |
| Locations | 1 site (NEW YORK, UNITED STATES) |
| Trial ID | NIH-10988246 on ClinicalTrials.gov |
What this research studies
This research focuses on understanding the role of the SOX2 protein in squamous cell carcinoma (SCC), a type of skin cancer. It aims to explore how modifications to SOX2, particularly its phosphorylation, influence the behavior of cancer stem cells and their ability to either self-renew or differentiate into other cell types. By using both mouse models and patient-derived samples, the research will identify the molecular mechanisms that regulate these processes, potentially leading to new therapeutic strategies for SCC patients.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with cutaneous or head and neck squamous cell carcinoma.
Not a fit: Patients with other types of cancer or those without squamous cell carcinoma may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to innovative treatments that improve outcomes for patients with squamous cell carcinoma.
How similar studies have performed: Other research has shown promising results in targeting similar molecular pathways in cancer treatment, suggesting that this approach may also be effective.
Where this research is happening
NEW YORK, UNITED STATES
- NEW YORK UNIVERSITY SCHOOL OF MEDICINE — NEW YORK, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: SCHOBER, MARKUS — NEW YORK UNIVERSITY SCHOOL OF MEDICINE
- Study coordinator: SCHOBER, MARKUS
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: androgen independent prostate cancer, androgen indifferent prostate cancer, androgen insensitive prostate cancer, androgen resistance in prostate cancer, androgen resistant prostate cancer